ST1072 |
Catalog No.GC79707
One-Click Copy Product Info
|
ST1072 is an inhibitor of CerS4 and CerS6.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1402703-50-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, ST1072 (2 mg/kg; i.p.; daily; day -1 to day 28 post-transplant) significantly reduces chronic GVHD severity in an MHC-mismatched murine allogeneic bone marrow transplantation model, matching the efficacy of CerS6 knockout donor grafts[3]. ST1072 (1 mg/kg; i.p.; daily; day -1 to day 14 post-transplant) significantly reduces acute GVHD severity and improves survival while preserving the GVL effect against mixed-lineage leukemia in an MHC-mismatched murine allogeneic bone marrow transplantation model[3]. ST1072 (1 mg/kg; i.p.; daily; day -1 to day 14 post-transplant) significantly reduces donor T-cell expansion and migration to GVHD target organs in an MHC-mismatched murine allogeneic bone marrow transplantation model[3].
In Vitro, ST1072 (10 min preincubation, 30 min reaction) potently inhibits ceramide synthase activity in HCT-116 cell microsomes, with the highest potency against C18:0-dhCer synthesis (IC50 = 26.9 μM) followed by C16:0-dhCer (IC50 = 50.4 μM) and weaker activity against C24:0-dhCer (IC50 = 81.3 μM)[1]. ST1072 (0-80 μM; 48 h) reduces the viability of HCT-116 human colon cancer cells in a concentration-dependent manner starting at 20 μM after 48 h of incubation[1]. ST1072 (25 μM) significantly reduces C16:0-dhCer, C24:0-dhCer, and C24:1-dhCer levels in HeLa human cervical cancer cells after 48 h of incubation[1]. ST1072 (5-30 μM; 48 h) potently reduces ceramide levels in HeLa human cervical cancer cells, with the highest potency against C16:0-Cer (IC50 = 6.8 μM) followed by C14:0-Cer (IC50 = 12.2 μM) and C24:1-Cer (IC50 = 14.5 μM) after 48 h of incubation[1]. ST1072 (50 μM; 5 days) potently inhibits allogeneic proliferation and IFN-γ production in primary murine WT T cells[2]. ST1072 (50 μg/mL; 24 h-5 days) inhibits TCR-mediated N-RAS activation and downstream ERK signaling in primary mouse wild-type T cells, reducing IFN-γ production in CD4 T cells, an effect reversed by active N-RAS overexpression[3].
References:
[1]. Schiffmann S, et al. Inhibitors of specific ceramide synthases. Biochimie. 2012 Feb;94(2):558-65.
[2]. Sofi MH, et al. Ceramide synthesis regulates T cell activity and GVHD development. JCI insight. 2017 May 18;2(10):e91701.
[3]. Sofi MH, et al. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia. 2022 Jul;36(7):1907-1915.
| Cas No. | 1402703-50-7 | SDF | |
| Formula | C28H41NO4 | M.Wt | 455.63 |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1948 mL | 10.9738 mL | 21.9476 mL |
| 5 mM | 439 μL | 2.1948 mL | 4.3895 mL |
| 10 mM | 219.5 μL | 1.0974 mL | 2.1948 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)